<p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 的股價在週五下跌了 2.9%。該公司股價最低觸及 48.87 美元，最後交易價為 49.92 美元。在交易過程中，共成交 24,034,551 股，較平均交易量 18,134,518 股增加了 33%。該股票之前的收盤價為 51.40 美元。</p>
<p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<ul>
<li>Hims &amp; Hers 股票因基本面和擠壓潛力而上漲</li>
</ul>
<p>多家券商對 HIMS 發佈了報告。花旗集團重申了 &#34;賣出&#34; 評級，並在週二發佈了 30.00 美元的目標價（上調自 25.00 美元）。Truist Financial 將 Hims &amp; Hers Health 的目標價從 39.00 美元下調至 33.00 美元，並在 4 月 10 日的研究報告中給予該公司 &#34;持有&#34; 評級。美國銀行在 4 月 29 日的報告中將 Hims &amp; Hers Health 的目標價從 22.00 美元上調至 26.00 美元，並給予該股票 &#34;表現不佳&#34; 的評級。Leerink Partners 在 2 月 25 日的研究報告中將 Hims &amp; Hers Health 的目標價從 24.00 美元上調至 40.00 美元，並給予該股票 &#34;市場表現&#34; 的評級。最後，Canaccord Genuity Group 在 2 月 19 日的報告中將 Hims &amp; Hers Health 的目標價從 38.00 美元上調至 68.00 美元，並給予該公司 &#34;買入&#34; 評級。兩位投資分析師對該股票給予了賣出評級，八位分析師給予了持有評級，三位分析師給予了買入評級。根據 MarketBeat 的數據，該股票的共識評級為 &#34;持有&#34;，平均目標價為 37.67 美元。</p>
<p><strong>閲讀我們對 Hims &amp; Hers Health 的最新分析</strong></p>
<h2>Hims &amp; Hers Health 價格表現</h2>
<ul>
<li>Hims &amp; Hers 股票因與諾和諾德的合作而飆升</li>
</ul>
<p>該股票的 50 日移動平均線為 32.74 美元，200 日移動平均線為 32.16 美元。該股票的市值為 113.1 億美元，市盈率為 115.73，貝塔值為 1.84。</p>
<p>Hims &amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近在 5 月 5 日發佈了季度財報。該公司報告季度每股收益為 0.20 美元，超出分析師一致預期的 0.12 美元，超出幅度為 0.08 美元。Hims &amp; Hers Health 的股本回報率為 10.97%，淨利潤率為 8.19%。該公司在本季度的收入為 5.8601 億美元，而分析師預期為 5.3521 億美元。去年同期，該公司每股收益為 0.05 美元。與去年同期相比，該公司的季度收入增長了 110.7%。分析師預計 Hims &amp; Hers Health, Inc. 本年度將發佈 0.29 美元的每股收益。</p>
<h2>內部買賣情況</h2>
<ul>
<li>Hims 的減肥擴展：真正的增長還是僅僅是炒作？</li>
</ul>
<p>在其他新聞中，內部人士 Michael Chi 於 2 月 10 日星期一出售了 7,259 股該公司的股票。股票以平均價格 43.28 美元出售，總交易額為 314,169.52 美元。交易完成後，該內部人士現在直接持有 193,601 股公司股票，價值 8,379,051.28 美元。此交易代表其持股減少了 3.61%。該出售在與證券交易委員會的法律文件中披露，文件可通過 SEC 網站獲取。此外，內部人士 Soleil Boughton 於 2 月 18 日星期二出售了 4,152 股公司的股票。該股票以平均價格 60.69 美元出售，總價值為 251,984.88 美元。出售後，該內部人士現在持有 157,345 股公司股票，價值 9,549,268.05 美元。該交易代表其持股減少了 2.57%。該出售的披露信息可以在此找到。內部人士在上個季度出售了價值 25,790,311 美元的 650,500 股公司股票。17.71% 的股票由公司內部人士持有。</p>
<h2>對 Hims &amp; Hers Health 的對沖基金看法</h2>
<p>對沖基金最近買入和賣出了該公司的股票。Means Investment CO. Inc. 在第四季度將其在 Hims &amp; Hers Health 的持股增加了 23.5%。Means Investment CO. Inc. 現在持有 50,040 股公司股票，價值 1,210,000 美元，在上個季度又購買了 9,508 股。Raymond James Financial Inc. 在第四季度獲得了 Hims &amp; Hers Health 的新頭寸，價值約 18,048,000 美元。阿拉斯加州財政部在第四季度購買了 Hims &amp; Hers Health 的新股份，價值約 2,628,000 美元。Pacer Advisors Inc. 在第四季度獲得了 Hims &amp; Hers Health 的新股份，價值約 374,000 美元。最後，Genesee Capital Advisors LLC 在第四季度獲得了 Hims &amp; Hers Health 的新頭寸，價值 889,000 美元。63.52% 的股票由機構投資者持有。</p>
<h2>關於 Hims &amp; Hers Health</h2>
<p>(獲取免費報告)</p>
<p>Hims &amp; Hers Health, Inc. 運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病學和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更喜歡的五隻股票超過 Hims &amp; Hers Health</li>
<li>三隻值得購買和持有的醫療保健分紅股票</li>
<li>谷歌在核反應堆上大舉投資——你應該投資嗎？</li>
<li>什麼是 MACD 指標以及如何在交易中使用它</li>
<li>台灣半導體因芯片限制而有新的上漲理由</li>
<li>三隻天然氣股票提供優厚的分紅收益</li>
<li>為什麼近 20 位分析師在財報後上調 Meta 目標價</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
<p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HIMS

<p>Hims & Hers Health（紐約證券交易所代碼：HIMS）的股價下跌了 2.9%，至 49.92 美元，交易量增加了 33%。分析師的評級意見不一，花旗集團維持 “賣出” 評級，目標價為 30 美元，而 Canaccord Genuity 將目標價上調至 68 美元，並給予 “買入” 評級。該公司報告的季度每股收益為 0.20 美元，超出預期，營收同比增長了 110.7%。內部交易活動中，高管進行了大量股票出售，對沖基金也在積極買入和賣出股票</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price traded down 2.9% on Friday . The company traded as low as $48.87 and last traded at $49.92. 24,034,551 shares changed hands during trading, an increase of 33% from the average session volume of 18,134,518 shares. The stock had previously closed at $51.40.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 的股價在週五下跌了 2.9%。該公司股價最低觸及 48.87 美元，最後交易價為 49.92 美元。在交易過程中，共成交 24,034,551 股，較平均交易量 18,134,518 股增加了 33%。該股票之前的收盤價為 51.40 美元。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>Hims &amp; Hers Stock Rises on Fundamentals and Squeeze Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers 股票因基本面和擠壓潛力而上漲</li>
</ul>
</div><p>A number of brokerages have issued reports on HIMS. Citigroup reaffirmed a &#34;sell&#34; rating and issued a $30.00 target price (up from $25.00) on shares of Hims &amp; Hers Health in a research note on Tuesday. Truist Financial lowered their price objective on shares of Hims &amp; Hers Health from $39.00 to $33.00 and set a &#34;hold&#34; rating for the company in a research note on Thursday, April 10th. Bank of America boosted their price target on shares of Hims &amp; Hers Health from $22.00 to $26.00 and gave the stock an &#34;underperform&#34; rating in a report on Tuesday, April 29th. Leerink Partners raised their price objective on shares of Hims &amp; Hers Health from $24.00 to $40.00 and gave the stock a &#34;market perform&#34; rating in a research report on Tuesday, February 25th. Finally, Canaccord Genuity Group raised their target price on Hims &amp; Hers Health from $38.00 to $68.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and an average target price of $37.67.</p>
<div class="lb-trans"><p>多家券商對 HIMS 發佈了報告。花旗集團重申了 &#34;賣出&#34; 評級，並在週二發佈了 30.00 美元的目標價（上調自 25.00 美元）。Truist Financial 將 Hims &amp; Hers Health 的目標價從 39.00 美元下調至 33.00 美元，並在 4 月 10 日的研究報告中給予該公司 &#34;持有&#34; 評級。美國銀行在 4 月 29 日的報告中將 Hims &amp; Hers Health 的目標價從 22.00 美元上調至 26.00 美元，並給予該股票 &#34;表現不佳&#34; 的評級。Leerink Partners 在 2 月 25 日的研究報告中將 Hims &amp; Hers Health 的目標價從 24.00 美元上調至 40.00 美元，並給予該股票 &#34;市場表現&#34; 的評級。最後，Canaccord Genuity Group 在 2 月 19 日的報告中將 Hims &amp; Hers Health 的目標價從 38.00 美元上調至 68.00 美元，並給予該公司 &#34;買入&#34; 評級。兩位投資分析師對該股票給予了賣出評級，八位分析師給予了持有評級，三位分析師給予了買入評級。根據 MarketBeat 的數據，該股票的共識評級為 &#34;持有&#34;，平均目標價為 37.67 美元。</p>
</div><p><strong>Read Our Latest Analysis on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Hims &amp; Hers Health 的最新分析</strong></p>
</div><h2>Hims &amp; Hers Health Price Performance</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 價格表現</h2>
</div><ul>
<li>Hims &amp; Hers Stock Soars on Novo Nordisk Collaboration</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers 股票因與諾和諾德的合作而飆升</li>
</ul>
</div><p>The stock's fifty day moving average is $32.74 and its two-hundred day moving average is $32.16. The stock has a market capitalization of $11.31 billion, a P/E ratio of 115.73 and a beta of 1.84.</p>
<div class="lb-trans"><p>該股票的 50 日移動平均線為 32.74 美元，200 日移動平均線為 32.16 美元。該股票的市值為 113.1 億美元，市盈率為 115.73，貝塔值為 1.84。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims &amp; Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. During the same period in the previous year, the company earned $0.05 earnings per share. The company's quarterly revenue was up 110.7% compared to the same quarter last year. Analysts expect that Hims &amp; Hers Health, Inc. will post 0.29 EPS for the current year.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近在 5 月 5 日發佈了季度財報。該公司報告季度每股收益為 0.20 美元，超出分析師一致預期的 0.12 美元，超出幅度為 0.08 美元。Hims &amp; Hers Health 的股本回報率為 10.97%，淨利潤率為 8.19%。該公司在本季度的收入為 5.8601 億美元，而分析師預期為 5.3521 億美元。去年同期，該公司每股收益為 0.05 美元。與去年同期相比，該公司的季度收入增長了 110.7%。分析師預計 Hims &amp; Hers Health, Inc. 本年度將發佈 0.29 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣情況</h2>
</div><ul>
<li>Hims’ Weight Loss Expansion: Real Growth or Just Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims 的減肥擴展：真正的增長還是僅僅是炒作？</li>
</ul>
</div><p>In other news, insider Michael Chi sold 7,259 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $43.28, for a total transaction of $314,169.52. Following the completion of the transaction, the insider now directly owns 193,601 shares of the company's stock, valued at $8,379,051.28. This trade represents a 3.61 % decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. The trade was a 2.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 650,500 shares of company stock worth $25,790,311 in the last quarter. 17.71% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Michael Chi 於 2 月 10 日星期一出售了 7,259 股該公司的股票。股票以平均價格 43.28 美元出售，總交易額為 314,169.52 美元。交易完成後，該內部人士現在直接持有 193,601 股公司股票，價值 8,379,051.28 美元。此交易代表其持股減少了 3.61%。該出售在與證券交易委員會的法律文件中披露，文件可通過 SEC 網站獲取。此外，內部人士 Soleil Boughton 於 2 月 18 日星期二出售了 4,152 股公司的股票。該股票以平均價格 60.69 美元出售，總價值為 251,984.88 美元。出售後，該內部人士現在持有 157,345 股公司股票，價值 9,549,268.05 美元。該交易代表其持股減少了 2.57%。該出售的披露信息可以在此找到。內部人士在上個季度出售了價值 25,790,311 美元的 650,500 股公司股票。17.71% 的股票由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>對 Hims &amp; Hers Health 的對沖基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the business. Means Investment CO. Inc. grew its stake in Hims &amp; Hers Health by 23.5% during the fourth quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock worth $1,210,000 after buying an additional 9,508 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Hims &amp; Hers Health in the 4th quarter worth approximately $18,048,000. State of Alaska Department of Revenue bought a new stake in Hims &amp; Hers Health in the fourth quarter worth approximately $2,628,000. Pacer Advisors Inc. acquired a new stake in shares of Hims &amp; Hers Health during the 4th quarter worth approximately $374,000. Finally, Genesee Capital Advisors LLC acquired a new position in shares of Hims &amp; Hers Health during the 4th quarter valued at $889,000. 63.52% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>對沖基金最近買入和賣出了該公司的股票。Means Investment CO. Inc. 在第四季度將其在 Hims &amp; Hers Health 的持股增加了 23.5%。Means Investment CO. Inc. 現在持有 50,040 股公司股票，價值 1,210,000 美元，在上個季度又購買了 9,508 股。Raymond James Financial Inc. 在第四季度獲得了 Hims &amp; Hers Health 的新頭寸，價值約 18,048,000 美元。阿拉斯加州財政部在第四季度購買了 Hims &amp; Hers Health 的新股份，價值約 2,628,000 美元。Pacer Advisors Inc. 在第四季度獲得了 Hims &amp; Hers Health 的新股份，價值約 374,000 美元。最後，Genesee Capital Advisors LLC 在第四季度獲得了 Hims &amp; Hers Health 的新頭寸，價值 889,000 美元。63.52% 的股票由機構投資者持有。</p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>關於 Hims &amp; Hers Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc. 運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病學和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li>
<li>Google Is Betting Big on Nuclear Reactors—Should You?</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票超過 Hims &amp; Hers Health</li>
<li>三隻值得購買和持有的醫療保健分紅股票</li>
<li>谷歌在核反應堆上大舉投資——你應該投資嗎？</li>
<li>什麼是 MACD 指標以及如何在交易中使用它</li>
<li>台灣半導體因芯片限制而有新的上漲理由</li>
<li>三隻天然氣股票提供優厚的分紅收益</li>
<li>為什麼近 20 位分析師在財報後上調 Meta 目標價</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Hims & Hers Health (NYSE:HIMS) 股價下跌 2.9% - 現在是賣出的時候嗎？